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Abstract
Angiogenesis is the formation of neovasculature from preexisting microvessels. Several endogenous proteins regu-
late the balance of vessel formation and regression in the body including pigment epithelium–derived factor (PEDF),
which has been shown to be antiangiogenic and to suppress tumor growth. Using sequence homology and bioinfor-
matics, we previously identified several peptide sequences homologous to an active region of PEDF existing in mul-
tiple proteins in the human proteome. These short 11-mer peptides are found in a DEAH box helicase protein, CKIP-1
and caspase 10, and show similar activity in altering endothelial cell adhesion, migration and inducing apoptosis. We
tested the peptide derived from DEAH box helicase protein in a triple-negative MDA-MB-231 breast orthotopic xeno-
graft model in severe combined immunodeficient mice and show significant tumor suppression.
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Introduction
Angiogenesis has received much attention as a therapeutic target to
treat various pathologic diseases such as solid tumors. Tuning vascular
growth by endogenous proangiogenic and antiangiogenic factors pro-
vides a plethora of information useful for the development of thera-
peutic antiangiogenic agents. A review by Judah Folkman [1], the
pioneer in the studies of tumor angiogenesis, discussed multiple exper-
imentally identified proteins with antiangiogenic properties, one being
pigment epithelium–derived factor (PEDF). First identified as a retinal
factor, PEDF is now shown to be expressed across multiple tissues and
organs in the body including the brain, eye, heart, and lung [2–4].
PEDF was shown to inhibit the migration and proliferation of endo-
thelial cells, blocking the angiogenic effects of vascular endothelial
growth factor (VEGF) and fibroblast growth factor 2 (FGF-2) [5]. In
addition to being a potent antiangiogenic agent, PEDF possesses other
physiological properties including antitumor and neurotrophic activi-
ties [6,7]. Its anticancer effects, for example, in lung, ovarian, and breast
cancer, have been further characterized [8].
The crystal structure of PEDF was resolved, showing a distinct
asymmetric charge distribution and reactive center loop [9]. Further
analysis revealed distinct regions with antiangiogenic activity [10], in-
cluding a 34-mer region and upstream TGA fragment and a 44-mer
neurotrophic region [11]. The 34-mer and TGA sequences induced
c-jun–NH2 kinase (JNK) phosphorylation and induced apoptosis of
endothelial cells. Additional studies characterized the 34-mer region
and identified a potent 18-mer active segment within the 34-mer re-
gion that inhibited angiogenesis by blocking endothelial cell chemotaxis
and suppressed prostate (PC-3) and renal cell carcinoma (RENCA)
tumor growth in vivo [12].
Bioinformatics methodology revealed three sequences in the human
proteome similar to the TGA epitope [13]. These fragments are
contained in several proteins including the RNA helicase DEAH box
helicase protein, the pleckstrin homology domain-containing protein
casein kinase 2–interacting protein 1 (CKIP-1), and apoptotic factor
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caspase 10. Physiologically distinct, these parent proteins have many
diverse roles including releasing RNA from ribosomes (DEAH box
helicase protein) [14], regulating cell differentiation and apoptosis
(CKIP-1) [15], and initiating apoptosis (caspase 10) [16]. Although
these proteins have been previously characterized in part, the bio-
informatics methodology used in our laboratory and experimental
screening described in the present work show antiangiogenic activity
resides within these proteins previously having been unrecognized as
containing antiangiogenic potential.
Breast cancer has been shown to be angiogenesis dependent [17–
19]. Worldwide, breast cancer remains a major killer, contributing to
more than 458,000 deaths annually and 1.4 million newly diagnosed
cases [20]. Triple-negative breast cancer represents a heterogeneous
subpopulation of breast tumors, accounting for ∼15% of breast tumors
and is not amenable to standard hormone therapy, contributing to poor
prognosis and survival [21]. In this study, we focus on the aggressive
MDA-MB-231 triple-negative breast cancer cell line owing to the
unmet medical need in treating triple-negative breast cancer.
We show that the bioinformatically identified serpin peptides, de-
rived from a DEAH box helicase protein (seq: EIELVEEEPPF), which
we name SP6001, SP6023 from CKIP-1 (seq: TLDLIQEEDPS), and
SP6024 from caspase 10 (seq: AEDLLSEEDPF), are potent inducers of
endothelial cell apoptosis as measured by caspase 3/7 release. Interest-
ingly, all three peptides also increase endothelial cell adhesion, and
SP6001 sustains phosphorylation of focal adhesion kinase (FAK), con-
sequently, diminishing cell migration. Most significantly, we show that
SP6001 potently suppresses growth of MDA-MB-231 breast tumors
through intraperitoneal or subcutaneous administration; therefore,
there is potential for this and other serpin-derived peptides to be devel-
oped as therapeutic antiangiogenic agents against breast cancer.
Materials and Methods
Peptide Synthesis and Handling
Peptides were produced by a commercial provider (American
Peptide, Sunnyvale, CA) using solid-phase synthesis. Purity was guar-
anteed to be more than 95% as determined by HPLC and MS data
provided by the manufacturer. A scrambled sequence was generated
for SP6001 identified herein as SP6001SCR (PEFEPEIEVEL) as a
separate control. For in vitro experiments, peptides were solubilized
in 1% dimethyl sulfoxide (DMSO) and phosphate-buffered saline
(PBS) and stored at −20°C. Total DMSO content in all experiments
in all wells was held at parity. For in vivo experiments, the peptide was
solubilized in 5% DMSO and PBS, and a negative control of 5%
DMSO and PBS was injected for tumor studies. Peptide was injected
daily at 1 or 5 mg/kg intraperitoneally (i.p.) or subcutaneously (s.c.).
Cell Culture
For in vitro experiments, human umbilical vein endothelial cells
(HUVECs) were purchased from a commercial provider (Lonza,
Walkersville, MD). Cells were passaged at constant ratios, and passages 3
to 6 were used in all experiments according to manufacturer’s recommen-
dations. We use the endothelial basal medium-2 and endothelial growth
medium-2 bullet kit for cell passage and treatments, purchased from Lonza.
For breast xenograft assays, MDA-MB-231 breast cancer cells
were provided by Dr Zaver Bhujwalla’s group (JHMI Radiology and
Oncology), providing the following details about the cell line: MDA-
MB-231 breast cancer cells were purchased from the American Type
Culture Collection (ATCC, Manassas, VA) and used within 6 months
of obtaining them from ATCC. The cell line was tested and authen-
ticated by ATCC by two independent methods, the ATCC cyto-
chrome C oxidase I polymerase chain reaction assay and short
tandem repeat profiling using multiplex polymerase chain reaction. Cells
were propagated in RPMI-1640 medium (Gibco, Carlsbad, CA), con-
taining 10% FBS and 1% penicillin/streptomycin, and grown at 37°C
and 5% CO2 under standard conditions.
Cell Adhesion Assay
A real-time cell adhesion assay was completed using a RT-CIM system
(ACEA Biosciences, Inc, San Diego, CA) and E-plates (Roche, IN),
which are 16-well plates suitable for cell culture and contain sensor
electrodes. The change in impedance is measured by electrodes and
expressed as a cell index, which is proportional to the degree of cell adhe-
sion to the wells.HUVECswere gently trypsinized and plated at a density
of 25,000 cells/well in the presence or absence of serpin peptides at 10 and
100 μM.Cells were allowed to settle at room temperature for 30minutes
and then loaded into the RT-CIM system. Values are scaled to percent
increase above negative control (complete endothelial cell media) and
taken at 1.5 hours. Statistical significance was determined at *P < .05
by Student’s t test and compared with the negative control.
Western Blot Analysis
HUVECs were grown in complete endothelial cell media, plated
in six-well tissue culture-treated plates at high density (360,000 cells/
well), and allowed to adhere for 2 hours. At this point, the medium was
removed; fresh endothelial cell media, SP6001 or SP6001SCR (10 μM)
with VEGF, or VEGF alone at 20 ng/ml were added, and the cells were
incubated at 37°C for 24 hours. The reactions were stopped by removing
themedium containing VEGF and adding PBS at 4°C and cell lysis buffer
(150 mM NaCl, 1 mM EDTA, 100 μl/ml protease inhibitors [Sigma,
St. Louis,MO], 10 μl/ml phosphatase inhibitors [Sigma], and 1%Triton)
was added after removing the cold PBS. The cell lysates were spun for
15 minutes at 14,000g to remove cell membranes and debris and were
separated by SDS-PAGE; the transferred blots were blocked for 1 hour
with 5%milk and 1% bovine serum albumin in Tris-buffered saline and
Tween. The 4G10 pan-tyrosine phosphorylation antibody at 1:2000
dilution (Santa Cruz Biotechnology, Inc, Santa Cruz, CA) was added,
and the blot was incubated overnight. Secondary antibodies were added
the next day at 1:2000 dilution and the phosphorylated protein bands
were detected by chemiluminescence detection reagent (GE Healthcare,
Little Chalfont, United Kingdom). Blots were stripped and probed with
FAK primary antibody (Cell Signaling Technology, Inc, Danvers, MA).
We followed a similar protocol for analysis of pJNK-1. Briefly,
SP6001 or SP6001SCR were applied at 1, 10, and 30 μM for 4 hours,
and cells were lysed with cell lysis buffer, separated by SDS-PAGE,
and probed with pJNK-1 antibody (Cell Signaling Technology, Inc).
Blots were then stripped and probed for JNK-1 (Cell Signaling
Technology, Inc). Experiments were repeated at least once. The ratio
of phospho-protein to total protein was quantified with ImageJ
software (National Institutes of Health, Bethesda, MD).
Cell Migration Assay
We used the Oris Pro migration assay (Platypus Technologies,
Madison, WI), a modified wound healing assay to assess SP6001
effects on cell migration. Plates are 96-well tissue culture plates that
contain stoppers that block the center of the wells. HUVECs were
plated at 20,000 cells/well in the presence or absence of peptide
SP6001 at 25, 50, or 100 μM and SP6001SCR at 10, 50, or 100 μM
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in complete endothelial cell media and were allowed to adhere. Two
hours later, the stoppers were removed, and the cells were allowed to
migrate into the center of the well for 20 hours, at which point cells
were stained with calcein AM (Invitrogen, Carlsbad, CA), and fluores-
cence was measured with a fluorescent Victor V plate reader (Perkin
Elmer, Waltham, MA). In some wells, stoppers were removed only after
20 hours to determine background migration, which was negligible.
Apoptosis Assay
A Caspase-Glo 3/7 Assay apoptosis detection assay was used to deter-
mine whether the peptides were causing endothelial cells to undergo ap-
optosis (Promega, Madison, WI). Briefly, cells were plated at 5000 cells/
well in opaque 96-well plates to minimize well-to-well crosstalk. The
next morning, the cells were serum starved for 24 hours by replacing
complete medium with serum-free media. A combination of basic
fibroblast growth factor (bFGF)/VEGF (30/10 ng/ml) with or without
peptide (0.1, 1 or 10 μM) was added at this point. Forty-eight hours
later, the Caspase-Glo chemiluminescent substrate (100 μl/well) was
added, and luminescence was measured with a Victor V plate reader
(Perkin Elmer). A serum-free medium control was used as an apoptosis
inducer. Each concentration of peptide was tested in triplicate, and
the experiments were repeated three times. The degree of apoptosis in
wells containing peptide is compared to only bFGF/VEGF–treated
wells. P values for the Student’s t test were calculated and considered
to be significant if they are P < .01. Experimental values shown are a
composite graph of n = 3 independent experiments.
MDA-MB-231 Breast Xenograft Assay
Orthotopic breast xenografts were established in severe combined
immunodeficient (SCID) mice using previously established techniques
[22]. Briefly, 2 × 106 cells were injected into the mammary fat pad of
animals, and tumors were allowed to grow to a palpable starting size
(∼100 mm3), which usually took 2 to 3 weeks. The mice were random-
ized and grouped into sets of eight for control or 1- or 5-mg/kg peptide
treatments. There was no statistical difference in starting values among
sets as determined by P values from Student’s t test. Tumor sizes were
determined every fourth day using calipers and applying the formula
V = ab2/2, where a is the long axis and b is the short axis of the tumor.
The peptides were administered daily i.p. or s.c. into the flank of the
animal for a total of 25 days. Statistical significance was determined on
Figure 1. Serpin sequences and their activities in cell adhesion and migration assays. (A) Bioinformatics methodology showing novel
sequences in the human proteome termed SP6001, SP6023, and SP6024. We generated a scrambled sequence based on the original
SP6001 peptide for test in adhesion assays. (B) SP6001, SP6023, and SP6024 promote endothelial cell adhesion. Adhesion in the presence
of SP6001 is significant over the complete medium control at 100 μM. (C) Oris Pro endothelial cell migration assay for HUVECs. Cells were
plated for 2 hours in the presence of SP6001 or complete medium around stoppers, which were then removed and cells were then allowed
to migrate. After 20 hours, cells were stained with calcein AM and fluorescence intensity measured with a Victor V plate reader. (D) Oris
Pro endothelial migration assay testing SP6001SCR. (E) Western blot analysis showing that SP6001 promotes endothelial cell adhesion
by sustaining phosphorylation of FAK over time in the presence of VEGF for 24 hours versus untreated cells and VEGF-treated cells. The
scrambled peptide did not show this same increase. (F) pFAK quantification for SP6001 (*P < .05) and (G) SP6001SCR.
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termination of the experiment by Student’s t test, and P values shown
compare PBS-treated controls and peptide-treated groups.
Immunohistochemical Staining and Quantification
After the sacrifice of animals on day 25 of the experiment, the tumors
were excised and stored in a zinc-based fixative (BD Biosciences, San
Jose, CA) for 2 weeks and sent to the JHMI Immunohistochemistry
Core Facility where they were centrally cross-sectioned and embedded
in paraffin wax. Samples were then sent to Covance, Inc (Princeton,
NJ), for immunohistochemical staining for the CD34 antigen. After
receipt of images, they were quantified for CD34 staining by FRiDA
(free software available from Johns Hopkins University, Baltimore,
MD) and measured pixel intensity at 20× magnification/frame. Statis-
tical significance was assessed at **P < .01 by Student’s t test. Images
shown are magnified at 4× to visually show greater surface area.
Results
The three bioinformatically identified serpin domain–derived se-
quences enhanced adhesion of endothelial cells by similar amounts,
although SP6001 was the only statistically significant result above the
non–peptide-treated negative control (Figure 1B). The scrambled
peptide, with the same amino acid content as SP6001, showedmarkedly
reduced activity from the native sequence and was not statistically dif-
ferent from the negative complete medium control. SP6001 but not
SP6001SCR also sustained FAK phosphorylation in the presence of
VEGF as determined by Western blot analysis (Figure 1E). VEGF is
known to induce FAK phosphorylation, and in the VEGF-treated controls,
this phosphorylation decreased during 24 hours. SP6001 constitutively
activates FAK for 24 hours in endothelial cells as determined by the ratio
of pFAK (4G10) to FAK. Figure 1F and Figure 1G quantify this effect
and show SP6001 but not SP6001SCR increase pFAK. In the endothelial
cell migration assay, SP6001 decreased HUVEC migration at 100 μM
compared with the complete medium control (Figure 1C). A serum-free
medium control was also taken (containing no chemoattractant; data not
shown) and was negligible compared to the induction of migration by
complete media. The scrambled peptide, SP6001SCR, shows markedly
reduced activity from SP6001 in migration and is not statistically different
from the complete medium control at 10, 50, or 100 μM (Figure 1D).
These serpin peptides were further characterized by showing that
they induce apoptosis of HUVECs in the presence of bFGF and
VEGF as measured by caspase 3/7 release (Figure 2A). In this case,
all peptides behaved similarly by increasing apoptosis significantly
compared to bFGF/VEGF treatment. Some peptide concentrations
were significantly more apoptotic than the serum-free medium control
(**P < .01). All peptides tested have a similar biphasic profile with
activity peaking at 1 μM, consistent with previously published results
[11]. This effect was most prominent during 48 hours of peptide treat-
ment. SP6001 but not the scrambled control also begins inducing JNK-1
stress kinase phosphorylation at 4 hours in comparison to untreated con-
trols (Figure 2B). These results are quantified in Figure 2, C and D.
SP6001 was then tested in vivo against a triple-negative MDA-
MB-231 orthotopic breast xenograft model. Compared to the PBS-
Figure 2. Serpin-derived peptides induce apoptosis in HUVECs. (A) Caspase 3/7 assay showing an increase in caspase 3/7 for peptide-
treated cells in the presence of bFGF and VEGF (30/10 ng/ml) after 48 hours. Values are normalized to 1 (bFGF/VEGF control). **Significant
compared to bFGF/VEGF controls for P< .01. (B) Western blot analysis showing JNK-1 stress kinase phosphorylation increases on SP6001
administration over SP6001SCR at 4 hours (1, 10, and 30 μM SP6001 or SP6001SCR treatment). Quantification of pJNK-1 increase for
SP6001 (C) and SP6001SCR (D).
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treated controls, SP6001 significantly suppressed breast tumor growth
at 5 mg/kg (i.p. injection; Figure 3A) and 5 mg/kg (s.c. injection;
Figure 3B). The subcutaneous peptide administration had a more
pronounced effect than i.p. administration when comparing mean
tumor volumes on day 25 (687 vs 453 mm3, respectively). Both values
were statistically lower than PBS-treated control, which had a final
value of 1274 mm3 on day 25. At 1 mg/kg, the i.p. injection was very
similar to control with virtually no tumor-suppressing activity, although
s.c. injection again showed improved activity versus PBS-treated control
but not quite statistically significant (P = .125). Immunohistochemistry
showed that at 5-mg/kg subcutaneous injection, there were signifi-
cantly fewer vessels as marked by CD34 staining versus the control
(Figure 3C ). Microvessels were quantified and confirmed a 43%
decrease in CD34 from the PBS-treated control for SP6001 5 mg/kg
s.c., significant at **P < .01 (Figure 3D).
Discussion
Triple-negative breast cancer is a virulent disease with poor prognosis
and few treatment options. Bevacizumab, a VEGF-neutralizing anti-
body, initially showed promise and was approved by the Food and
Drug Administration as breast cancer therapy in combination with
chemotherapy [23]; however, in 2011, the FDA recommended remov-
ing the breast cancer indication from bevacizumab because it did not
lead to an increase in overall survival of patients [24]. Breast cancer is
an angiogenesis-dependent disease and may be amenable to peptide-
based therapies, which do not target standard hormone receptors. In
this study, we experimentally show that bioinformatically identified
serpin peptides suppress tumor growth by altering adhesion/migration
of endothelial cells and inducing endothelial cell apoptosis.
The SP6001, SP6023, and SP6024 peptides have similar sequences
and are found in the human proteome. Their parent proteins are not
Figure 3. MDA-MB-231 breast xenograft assay. SP6001 significantly suppresses breast tumor growth by two methods of administration—
intraperitoneal (i.p.) (A) and subcutaneous (s.c.) (B) peptide delivery. Tumorsweremeasured every fourth day. Peptideswere injected daily at
1 or 5 mg/kg. (C) CD34 immunohistochemistry for endothelial cells in tumor cross sections. (D) SP6001 at 5 mg/kg subcutaneous admin-
istration significantly decreases CD34 below PBS-treated controls (**P < .01).
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known to have antiangiogenic properties. The similarity in sequence
and activity suggest a common mechanism of action for this peptide
family. In this study, we show that these serpin-derived peptides in-
crease cell adhesion above a negative control, and SP6001, but not the
scrambled control, sustains phosphorylation of FAK. FAK is respon-
sible for tyrosine phosphorylation in many focal adhesion-associated
proteins to sustain integrin-mediated adhesion [25]. In a previous study,
Ek et al. [26] generated four 25-mer PEDF-derived peptides termed
StVOrth-1, -2, -3, and -4 and showed that three sequences increased
adhesion of osteosarcoma cells, resulting in a reduction of their invasive-
ness. The serpin-derived peptides may also primarily exhibit their cellular
effects through this mechanism whereby adhesion is increased resulting
in a decrease in migration. In contrast, several nonserpin peptides are
antiangiogenic by blocking endothelial cell adhesion and migration, in-
cluding the proapoptotic peptide CIGB-300 [27], the human decorin
leucine-rich peptide LRR5 [28], and the galectin 1–binding peptide
Anginex [29]. The relative importance of endothelial cell adhesion and
how adhesion may determine efficacy of targeted therapies in tumor
angiogenesis by inhibiting endothelial cell migration should be further
characterized by more comprehensive peptide-peptide comparisons.
We show that serpin-derived peptides induce endothelial cell ap-
optosis by caspase 3/7 release and induction of JNK-1. These results
are consistent with previously published PEDF literature [8,11]. The
proapoptotic activity is biphasic for each peptide and peaks at 1 μM,
suggesting the presence of multiple receptors. JNK-1 may be acti-
vated by numerous stresses on the cell including UV light, reactive
oxygen species, and other stress factors contributing to apoptosis [30].
SP6001 but not the scrambled control increases pJNK-1.
SP6001 is potent when administered i.p. or s.c. in tumor-bearing
mice. Mean tumor volumes for 1- and 5-mg/kg dosing were lower in the
s.c. treatment compared to i.p. CD34 immunohistochemical staining of
the tumor, which was significantly lower in the case of 5 mg/kg s.c.
administration, confirming our hypothesis that the peptide is anti-
angiogenic and affects endothelial cells in the tumor microenvironment.
The improved activity after subcutaneous administration, namely, lower
tumor volume and decreased CD34 expression, suggests better bioavail-
ability of the peptide to the tumor microenvironment, which we plan to
more comprehensively study in future work. PEDF and phosphomi-
metic variants of the full-length protein have been proposed as treat-
ment for breast cancer [31]; however, to our knowledge, this is the
first study of short serpin-derived peptides showing efficacy in a breast
cancer model. Indeed, the efficacy of SP6001 suggests that these pep-
tides should be further optimized to become clinical candidates for
breast cancer treatment.
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